183 related articles for article (PubMed ID: 22884837)
1. Antisolvent crystallisation is a potential technique to prepare engineered lactose with promising aerosolisation properties: effect of saturation degree.
Kaialy W; Nokhodchi A
Int J Pharm; 2012 Nov; 437(1-2):57-69. PubMed ID: 22884837
[TBL] [Abstract][Full Text] [Related]
2. The influence of physical properties and morphology of crystallised lactose on delivery of salbutamol sulphate from dry powder inhalers.
Kaialy W; Martin GP; Larhrib H; Ticehurst MD; Kolosionek E; Nokhodchi A
Colloids Surf B Biointerfaces; 2012 Jan; 89():29-39. PubMed ID: 21962946
[TBL] [Abstract][Full Text] [Related]
3. Dry powder inhalers: mechanistic evaluation of lactose formulations containing salbutamol sulphate.
Kaialy W; Ticehurst M; Nokhodchi A
Int J Pharm; 2012 Feb; 423(2):184-94. PubMed ID: 22197772
[TBL] [Abstract][Full Text] [Related]
4. Effect of carrier particle shape on dry powder inhaler performance.
Kaialy W; Alhalaweh A; Velaga SP; Nokhodchi A
Int J Pharm; 2011 Dec; 421(1):12-23. PubMed ID: 21945739
[TBL] [Abstract][Full Text] [Related]
5. Improved aerosolization performance of salbutamol sulfate formulated with lactose crystallized from binary mixtures of ethanol-acetone.
Kaialy W; Ticehurst MD; Murphy J; Nokhodchi A
J Pharm Sci; 2011 Jul; 100(7):2665-84. PubMed ID: 21268026
[TBL] [Abstract][Full Text] [Related]
6. Characterisation and deposition studies of recrystallised lactose from binary mixtures of ethanol/butanol for improved drug delivery from dry powder inhalers.
Kaialy W; Martin GP; Ticehurst MD; Royall P; Mohammad MA; Murphy J; Nokhodchi A
AAPS J; 2011 Mar; 13(1):30-43. PubMed ID: 21057906
[TBL] [Abstract][Full Text] [Related]
7. Humidity-induced changes of the aerodynamic properties of dry powder aerosol formulations containing different carriers.
Zeng XM; MacRitchie HB; Marriott C; Martin GP
Int J Pharm; 2007 Mar; 333(1-2):45-55. PubMed ID: 17064863
[TBL] [Abstract][Full Text] [Related]
8. Influence of primary crystallisation conditions on the mechanical and interfacial properties of micronised budesonide for dry powder inhalation.
Kubavat HA; Shur J; Ruecroft G; Hipkiss D; Price R
Int J Pharm; 2012 Jul; 430(1-2):26-33. PubMed ID: 22449413
[TBL] [Abstract][Full Text] [Related]
9. Influence of the lactose grade within dry powder formulations of fluticasone propionate and terbutaline sulphate.
Le VN; Bierend H; Robins E; Steckel H; Flament MP
Int J Pharm; 2012 Jan; 422(1-2):75-82. PubMed ID: 22036653
[TBL] [Abstract][Full Text] [Related]
10. Dry powder inhalers: physicochemical and aerosolization properties of several size-fractions of a promising alterative carrier, freeze-dried mannitol.
Kaialy W; Nokhodchi A
Eur J Pharm Sci; 2015 Feb; 68():56-67. PubMed ID: 25497318
[TBL] [Abstract][Full Text] [Related]
11. Engineered mannitol as an alternative carrier to enhance deep lung penetration of salbutamol sulphate from dry powder inhaler.
Kaialy W; Momin MN; Ticehurst MD; Murphy J; Nokhodchi A
Colloids Surf B Biointerfaces; 2010 Sep; 79(2):345-56. PubMed ID: 20537870
[TBL] [Abstract][Full Text] [Related]
12. The enhanced aerosol performance of salbutamol from dry powders containing engineered mannitol as excipient.
Kaialy W; Martin GP; Ticehurst MD; Momin MN; Nokhodchi A
Int J Pharm; 2010 Jun; 392(1-2):178-88. PubMed ID: 20363301
[TBL] [Abstract][Full Text] [Related]
13. Development of a laser diffraction method for the determination of the particle size of aerosolised powder formulations.
Marriott C; MacRitchie HB; Zeng XM; Martin GP
Int J Pharm; 2006 Dec; 326(1-2):39-49. PubMed ID: 16942848
[TBL] [Abstract][Full Text] [Related]
14. Engineered mannitol ternary additives improve dispersion of lactose-salbutamol sulphate dry powder inhalations.
Kaialy W; Nokhodchi A
AAPS J; 2013 Jul; 15(3):728-43. PubMed ID: 23591748
[TBL] [Abstract][Full Text] [Related]
15. Understanding the effect of lactose particle size on the properties of DPI formulations using experimental design.
Guenette E; Barrett A; Kraus D; Brody R; Harding L; Magee G
Int J Pharm; 2009 Oct; 380(1-2):80-8. PubMed ID: 19596428
[TBL] [Abstract][Full Text] [Related]
16. Preparation and Evaluation of Surface Modified Lactose Particles for Improved Performance of Fluticasone Propionate Dry Powder Inhaler.
Singh DJ; Jain RR; Soni PS; Abdul S; Darshana H; Gaikwad RV; Menon MD
J Aerosol Med Pulm Drug Deliv; 2015 Aug; 28(4):254-67. PubMed ID: 25517187
[TBL] [Abstract][Full Text] [Related]
17. Treating mannitol in a saturated solution of mannitol: a novel approach to modify mannitol crystals for improved drug delivery to the lungs.
Kaialy W; Nokhodchi A
Int J Pharm; 2013 May; 448(1):58-70. PubMed ID: 23500603
[TBL] [Abstract][Full Text] [Related]
18. Effect of milling and sieving on functionality of dry powder inhalation products.
Steckel H; Markefka P; teWierik H; Kammelar R
Int J Pharm; 2006 Feb; 309(1-2):51-9. PubMed ID: 16377105
[TBL] [Abstract][Full Text] [Related]
19. Production of salbutamol sulfate for inhalation by high-gravity controlled antisolvent precipitation.
Chiou H; Li L; Hu T; Chan HK; Chen JF; Yun J
Int J Pharm; 2007 Feb; 331(1):93-8. PubMed ID: 17052870
[TBL] [Abstract][Full Text] [Related]
20. Agglomerate behaviour of fluticasone propionate within dry powder inhaler formulations.
Le VN; Robins E; Flament MP
Eur J Pharm Biopharm; 2012 Apr; 80(3):596-603. PubMed ID: 22198291
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]